DDInter379 DDInter927
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Cilostazol {u} (Compound) binds {v} (Gene) PDE3A
Cilostazol {u} (Compound) upregulates {v} (Gene) RRP8
Cilostazol {u} (Compound) palliates {v} (Disease) systemic scleroderma
Cilostazol {u} (Compound) downregulates {v} (Gene) PPP2R5E
Cilostazol {u} (Compound) causes {v} (Side Effect) Arthritis
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brivaracetam
Cilostazol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Adenosine
Cilostazol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Cilostazol {u} may lead to a major life threatening interaction when taken with {v} Fondaparinux
Cilostazol (Compound) binds PDE3A (Gene)
Cilostazol (Compound) upregulates RRP8 (Gene)
Cilostazol (Compound) palliates systemic scleroderma (Disease)
Cilostazol (Compound) downregulates PPP2R5E (Gene)
Cilostazol (Compound) causes Arthritis (Side Effect)
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Brivaracetam
Cilostazol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Adenosine
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Cilostazol may lead to a major life threatening interaction when taken with Fondaparinux